140
Participants
Start Date
December 14, 2016
Primary Completion Date
June 20, 2021
Study Completion Date
January 29, 2025
Durvalumab
Tremelimumab
Cross Cancer Institute, Edmonton
BCCA - Cancer Centre for the Southern Interior, Kelowna
BCCA - Vancouver Cancer Centre, Vancouver
CancerCare Manitoba, Winnipeg
QEII Health Sciences Centre, Halifax
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
London Regional Cancer Program, London
Ottawa Hospital Research Institute, Ottawa
University Health Network, Toronto
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal
The Research Institute of the McGill University, Montreal
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Collaborators (1)
AstraZeneca
INDUSTRY
Canadian Cancer Trials Group
NETWORK